Clinical Trial Update: An Open-label Study That Will Test a Second Treatment Session of RZL-012. [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial evaluating a second treatment session of RZL-012 for submental fat has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Submental Fat

Drugs mentioned

• RZL-012

Snippet

Sponsor: Raziel Therapeutics Ltd. | Conditions: Submental Fat | Phase 2 | Status: COMPLETED